Reliability of the determination of the ventilatory threshold in patients with COPD by Dubé, Bruno-Pierre
 i 
 
Reliability of the determination of the ventilatory 

















Master of Science (M.Sc) in Exercise Science 
at 
Concordia University 











School of Graduate Studies 
 
This is to certify that the thesis prepared 
 
By :   Bruno-Pierre Dubé 
 
Entitled :  Reliability of the determination of the ventilatory threshold in patients 
with COPD 
 
And submitted in partial fulfillment of the requirements for the degree of 
Master of Science (Exercise Science) 
Complies with the regulations of the University and meets the accepted standards with 
respect to originality and quality.  
 
Signed by the final Examining Committee 
 
   ___________________________ Chair 
 
   ___________________________ Examiner 
 
   ___________________________ Examiner 
 
   ___________________________ Supervisor 
 
Approved by ____________________________________ 
   Graduate Program Director 
 
Date __________  ________________________________ 




The ventilatory threshold (VT) is a physiological turning point that can be used to guide 
for exercise prescription, as a tool to monitor response to an intervention and as a 
prognostic marker, but the presence of respiratory disease may limit the reliability of its 
measurement. This project aimed to determine the reliability of the assessment of the 
ventilatory threshold among human and computerized observers, in patients with chronic 
obstructive pulmonary disease (COPD) and controls. 
 
Methods 
VT was identified from incremental exercise testing graphs of 115 subjects (23 controls 
and 23 in each COPD severity class) by two human observers and a computer analysis, 
using the V-slope method and the VEM. Agreement between observers for VO2 at VT 
(VO2VT) and heart rate at VT (HRVT) were evaluated using intra-class correlation (ICC) 
for humans and Passing-Bablok regression analysis (human vs computer).  
 
Results 
For humans, ICCs for VO2VT were higher in controls [0.98 (0.97-0.99) both with V-slope 
and with VEM] than in COPD patients [0.72 (0.60-0.81) with V-slope and 0.64 (0.50-
0.74) with VEM]. Human and computerized values of VO2VT were interchangeable in 
controls, but not in COPD patients. FEV1 and peak-ventilation were independent 
predictors of a lesser reliability of VO2VT. Inter-observer differences in HRVT ranged 
from 2±1 beats/minute (controls) to 10±3 beats/minute (GOLD 4).  
 
Conclusions 
In COPD, the reliability of human estimation of VO2VT is less in than in controls and not 
interchangeable with a computerized analysis. This should be taken into account when 
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4.1.1 Epidemiology of COPD 
 
Chronic obstructive pulmonary disease (COPD) is a constellation of conditions 
characterized by persistent expiratory airflow limitation. Among the many reported 
phenotypes of COPD, the most prevalent remain the emphysema and chronic bronchitis 
variants. The prevalence of COPD varies widely across geographic regions(1). This is an 
effect of both technical differences in the assessment of COPD (for example, the use of 
self-administered questionnaires vs objective spirometric values, or the use of a fixed 
FEV1/FVC ratio vs a lower-limit of normal model)(2) and real differences across 
countries. As an example, in the largest international study of the prevalence of the 
disease, Global initiative for Obstructive Lung Disease (GOLD) stage II COPD in 
women ranged from about 5% in China to 17% in South Africa, and in men from 4% in 
Mexico to 23% in South Africa(1). In 2012, the age-standardized prevalence of COPD 
among Canadian men was 3.5% and in women 4.3%, with fluctuations of about 1% 
across provinces(3). 
 
COPD is the fourth leading cause of death in Canada, being responsible for almost 12 
000 deaths in 2013(3). In the United States, COPD has risen to third place in mortality 
causes since 2008(4), and was one of the few diseases showing an increase in mortality 
rate between 2008 and 2011(5). Although cigarette smoking showed a slow decline in the 
last 10 years in Canada(6), the repercussions of the epidemic of cigarette smoking in the 
20th century are still evident today, as evidenced by the high prevalence and burden of 
COPD. As such, although the mortality associated with COPD in men peaked in the mid-
1980’s in Canada, mortality in women is still slowly increasing, representing the later 
peak in smoking prevalence in this population(7). These observations, coupled to the fact 
that COPD is a vastly underdiagnosed disease(8), underline the crucial importance of its 
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early detection to allow for a timely and effective management of both its risk factors and 
its complications. 
  
Along with being a major economic burden (COPD-related costs approximate 3.94 
billion dollars in 2010 in Canada, and are expected to rise to 9.45 billion by 2030)(9), 
COPD is a cause of significant decrease in quality of life, which is related to the disease 
severity(10). 
 
4.1.2 Risk factors, pathogenesis and clinical consequences of COPD 
 
Worldwide, cigarette smoking remains the main risk factor associated with the 
development of COPD(11). In the last decades, evidence for other new determinant 
conditions, such as passive exposition to second-hand smoke, occupational exposures 
such as organic and inorganic dusts (i.e. asbestos, gold, cadmium, isocyanates, welding 
fumes and industrial cotton manufacturing)(12, 13) has increased. A growing concern in 
developing countries is the threat of indoor pollution (i.e. from biomass cooking and coal 
heating, especially in poorly ventilated areas), which is a newly identified risk factor for 
COPD(14, 15).  
 
COPD results from a gene-environment interaction: among with people with the same 
smoking history, not all will develop the disease(16). The well documented 
predisposition of patients with alpha-1 antitrypsin (A1AT) deficiency(17) to develop 
emphysema, even in the absence of cigarette smoking, is an example of this phenomenon. 
The absence of A1AT, which normally inhibits the tissue-damaging effects of neutrophil 
elastase, promotes unregulated pulmonary destruction of elastase, which mimicks the 
effects of cigarette smoke on the lung parenchyma. 
 
Pathologically, COPD is characterized by chronic inflammation of the respiratory tract, 
mediated by cytokines, chemokines (CCL2, CXCL1-8-9-10), adhesion molecules, 
inflammatory enzymes and reactive oxygen species(18), expressed by epithelial cells and 
macrophages in response to an inhaled irritant(19). These mediators cause a local cellular 
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self-perpetuating inflammatory reaction involving fibroblasts, neutrophils, Tc1 
lymphocytes and monocytes, which, through proliferation and production of enzymes 
(neutrophil elastase and matrix metalloproteinase-9)(20) will result in the hallmark 
pathological changes seen in COPD: small airway fibrosis, alveolar wall destruction 
(emphysema) and mucus hypersecretion(19). These alterations in the airway will induce 
the fixed expiratory airflow limitation that is characteristic of COPD(21). 
 
Although chronic cough and sputum production are common symptoms in COPD 
patients, it is dyspnea, especially on exertion, that is the cardinal clinical finding in these 
patients(16). Airflow obstruction causes increased work of breathing, increased airway 
resistance, gas-exchange inefficiency, intrinsic positive end-expiratory airway pressure 
and dynamic hyperinflation on exertion(21, 22). The resulting shortness of breath is the 
first step in a downward spiral of breathlessness that includes fear of dyspnea and 
immobilisation, which itself induces muscle mass wasting (muscle atrophy) and exercise 
anxiety and intolerance(23). This phenomenon is known to negatively impact 
prognosis(24) and, coupled to the well-described systemic exercise-limiting effects of 
COPD(25) (nutritional anomalies and ‘’pulmonary cachexia’’(26), skeletal muscle 
dysfunction(27), coronary artery disease(28), depression(29), cognitive decline(30) and 
osteoporosis(31)) make increasing exercise capacity a key goal in the management of 
COPD patients.  
 
4.1.3 Management of COPD 
 
Current guidelines(16, 32) place emphasis on two goals in the management of COPD: 
risk reduction (preventing disease progression and exacerbations) and symptoms 
reduction (relieving dyspnea, improving exercise tolerance and improving health status). 
Although smoking cessation and pharmacological agents (using inhaled short- and long-
acting beta2-agonists and anticholinergics) remain the mainstay of COPD management, 
few interventions have proven to be as effective as pulmonary rehabilitation (PR) in 
reaching these goals. PR has clearly been shown to reduce dyspnea, increase exercise 
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tolerance, improve quality of life, decrease healthcare utilisation and exacerbations in 
patients with even mild COPD(33-35).  
 
Compared with healthy controls however, COPD patients exhibit a wide range of 
ventilatory and circulatory anomalies during exercise, including a slower adaptation to 
increasing work (slower time constants for minute-ventilation (VE), VCO2 and O2 pulse), 
increased VE with decreased alveolar ventilation (VA) due to dynamic hyperinflation, 
increased work of breathing, oxygen desaturation and increase in right ventricular 
afterload(34, 36, 37), that all lead to marked exercise intolerance. Identifying the optimal 
intensity and modality of training in these patients, in order to balance the benefits of 
training with the risk/intolerance of exercising in these subjects, is therefore crucial, but 
difficult, and is still a matter of debate (34). Although the current PR guidelines(34) 
recommend endurance training based on the recommendations of the American College 
of Sports Medicine (i.e. with a goal of at least 60% of maximal work rate, either 
predicted or evaluated on an incremental exercise test(38), many patients with COPD 
cannot sustain or comply to this recommendation(39, 40). In light of these observations, 
and as an introduction to the following section, many studies have shown that an 
individualized training program based on each patient’s level of aerobic fitness (i.e. based 
on their ventilatory threshold) is both safe and effective in patients with COPD(41-45). 
 
4.2 Anaerobic threshold vs Ventilatory threshold 
 
4.2.1 Anaerobic threshold (AT) 
 
During exercise, muscle cells initially derive energy from adenosine triphosphate (ATP) 
molecules. ATP is the end-product of the aerobic cellular metabolism, in which glucose 
is sequentially converted to pyruvate and acetyl-CoA, which enters the Krebs cycle to 
produce ATP through oxidative phosphorylation. This aerobic process is highly efficient 
(30 ATP molecules per molecule of glucose)(46). During incremental exercise, a point is 
reached at which oxygen delivery (DO2) is insufficient to meet the increasing demands of 
muscle cells. From this point, anaerobic metabolism contribution to energy production 
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increases to further supplement energy production. This process is much less efficient 
(net gain of 2 ATP per glucose molecule) and results in the accumulation of lactic acid in 
the blood, as a by-product of pyruvate metabolism(47, 48). Lactic acid, having a very low 
pKa, will readily dissociate into lactate ions and protons, which are buffered by serum 
bicarbonates, producing water and carbon dioxide that can then be excreted by the 
lungs(49). Although there is controversy as to whether the AT is truly a ‘’threshold’’, (as 
some data suggests that blood lactate accumulation during exercise occurs continuously, 
or in a hyperbolic fashion(50, 51)), it is clear that the VO2 associated with the AT 
(VO2AT) represents a real metabolic turning point. Indeed, this point in exercise is 
associated with significant alterations in the ventilatory parameters – which form the 
premise for the concept of ventilatory threshold. 
 
4.2.2 Ventilatory threshold (VT) 
 
4.2.2.1 How to identify it 
 
With the advent of cardiopulmonary exercise 
testing (CPET) in the 1960’s, it was observed that 
both VE and VCO2 showed a break in the 
linearity of their increase during exercise, at a 
point approximately corresponding to AT(52-54). 
The term ‘’ventilatory’’ threshold was introduced 
to specify that this point in exercise had been 
identified using ventilation-derived parameters 
(figure 1), instead on relying directly on the 
measurement of serum lactic acid. 
 
Although the cut-off points of the respiratory 
coefficient (R) and VE were the first described 
methods of identifying VT, their correlation with 
serum lactate concentration (AT) was variable. 
Figure 1. Cut-off points of various indices 
during exercise – purportedly representing the 
AT. From reference 54. 
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Figure 2. V-slope method. The intersection point of 
2 regression lines show the inflection point of the 
relationship between VCO2 and VO2. From 
reference 64. 
Caiozzo et al. studied the correlation between different ventilatory indices and lactates 
values on 16 healthy individuals, and found correlations of 0.88 for VE and 0.39 for 
R(55). Green et al. showed that, in 10 healthy participants, the difference between AT 
and VT (estimated using VE plotted against VO2) was large when expressed as power 
output, reaching 383 kg/min)(56).  
 
Two non-invasive methods were showed to be more reliable in identifying the AT: 
1. The respiratory equivalent method (VEM). First described by Reinhard(54), the 
VEM uses a plot of both the ventilatory equivalent for O2 (VE/VO2) and for CO2 
(VE/VCO2) against work rate (W). VT is defined as the first point where there is 
an increase in VE/VO2 without a concomitant change in VE/VCO2. On 15 healthy 
subjects, correlation between the VEM and the AT was 0.94. Caiozzo et al. also 
evaluated VE/VCO2 for VT determination, and found a correlation of 0.93 with 
AT(55). 
2. The V-slope method, originally described by Beaver et al(57). This method uses a 
plot of VCO2 against VO2, with VT being the breaking point in the linearity of 
their relationship (figure 2). They proposed 
that the V-slope has the advantage of 
excluding minute ventilation (VE) from the 
graphical representation of the data, 
therefore truly only considering the 
metabolic compensation phenomenon 
(faster increase of VCO2 relative to VO2), 
without interference from the actual 
ventilatory rate or pattern, as can be seen in 
patients with hyperventilation syndromes, or COPD. In the original study, when 
compared with a mean value of VT derived from other methods (VEM, R, PETO2 
and PETCO2), with AT as a benchmark measure, the mean value of VT using the 
V-slope method was not different from the composite value, but much more 
reliable (coefficient of variance 0.023 vs 0.127). V-slope analysis was the only 
method that could identify a VT in all subjects. 
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4.2.2.2 Is there a true relationship between VT and AT? 
 
Although the rationale behind the VT is intuitive when considered under the 
aforementioned model where the excess CO2 produced by anaerobic metabolism has to 
be excreted by the lungs via an increase in minute ventilation and VCO2 (47, 49, 52, 53, 
57, 58), the link of causality between AT and VT has been challenged by some authors. 
Green et al.(56), Patessio et al.(59) and Gladden et al.(60) all showed that AT and VT 
occurred at significantly different moments during exercise in healthy subjects. More 
convincingly, Péronnet and Aguilaniu(61) argued that: 
1) It is impossible for any ‘’excess’’ nonmetabolic CO2 to be produced during exercise, 
as this would violate the law of mass conservation. The CO2 that is thought to be created 
from anaerobic metabolism in the Wasserman model is in fact already present in the 
blood, in the form of bicarbonates formed from CO2 during normal aerobic metabolism. 
Thus, the disproportionate increase in ventilation during exercise cannot be explained by 
‘’new’’ CO2 synthesis.  
2) The assertion that VCO2 (measured at the mouth, as in CPET) determines VE is wrong, 
as VCO2 at the mouth does not equal CO2 delivery to the lungs (QVCO2 – true CO2 
production). The fact that VCO2 increases disproportionally during exercise (as seen in 
the V-slope method) cannot be said to represent an increase in CO2 production, but rather 
could be due to hyperventilation, with an increase in CO2 release at the mouth, without 
change in CO2 production.  
 
This can be mechanistically shown using the developed equation of alveolar gases(61): 
VCO2 = VE	×PaCO2	×(1 − VDVT)K  
It clearly shows that, for a given value of dead space ratio, VCO2 is determined by VE 
(and PaCO2) – not the other way around. Of note, this argument was mentioned by 
Wasserman in the past(53), but dismissed on the grounds that the total quantity of CO2 




Finally, and most importantly, Hagberg et al.(62) conducted a study on 4 patients with 
McArdle syndrome, an autosomal recessive genetic disease in which patients lack the 
enzyme glycogen phosphorylase, and therefore are incapable of producing lactic acid 
during exercise. During incremental testing, all patients showed a distinct and 
disproportionate increase in VE similar to healthy controls, despite no change in serum 
lactate values and an increase, rather than a decrease, in serum pH. 
 
These observations led to the search for another potential trigger for the VT – other than 
lactate production(63). Potassium has been implicated as a potential humoral trigger of 
ventilation during exercise(64). In anesthetised cats, potassium stimulates ventilation 
through excitation of chemoreceptors in the carotid bodies, and surgical denervation of 
these receptors prevent this phenomenon(65). In patients with McArdle disease, serum 
potassium levels track VE better than serum lactate levels, both during exercise and 
recovery(66). It has also been shown that VT correlates well with a ‘’fatigue threshold’’ 
on EMG(67, 68), which leads to the possibility of a higher neural activity controlling 
ventilation during exercise, possibly in relation to motor unit recruitment(69).  
 
4.2.2.3 Use of the VT in clinical practice 
 
Despite the uncertainties outlined in the last section, there remains little doubt that, 
independently of its underling mechanism, the VT represent a pivotal point for 
metabolism during exercise, and is correlated to a wide variety of relevant clinical 
outcomes.  
 
Work beyond the VT is associated with significantly reduced exercise tolerance(58) and 
major metabolic changes such as metabolic acidosis, a slowing of VO2 and VCO2 
kinetics, an increase in oxygen debt, a disproportionate increase in minute ventilation 
increases compared to metabolic demand(47) and a sharp rise in subjective dyspnea(70). 
Conversely, exercise performed before VT, in the hypothetical availability of enough 
substrate, can theoretically be sustained indefinitely(71).  
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Figure 3. Mean blood lactate concentration during 
exercise when applying a fixed 70-75% VO2max 
intensity. From reference 81. 
 
VT is usually expressed either in ml or in %VO2max predicted, and its normal value 
varies with age, sex and fitness level, but usually lies between 50-60% of %VO2max 
predicted(71). VT is widely regarded as one of the best estimator of overall fitness(71-
74), and it is responsive to aerobic training, both in normal subjects and patients with 
chronic lung disease(75-79).  
 
One of the main clinical uses of the VT is for 
exercise prescription. Although the ACSM 
suggests heart rate (HR – in percentage of 
HR reserve or percentage of HRpeak) or a 
percentage of VO2 reserve as a guide to 
prescribe exercise(38), evidence suggests 
that this may not be appropriate for all 
patients, especially those with heart or lung 
disease. In 2011, Hofmann and 
Tschakert(80) published a review paper 
highlighting the fact that using fixed 
percentages of either HRR or VO2max to 
prescribe exercise can result in a wide range 
of different training intensities, both 
potentially above or below VT, which could respectively result in exercise inducing 
undue fatigue and intolerance (above VT) or of too low intensity to provide benefits 
(below VT). They suggested using an individualised threshold (either VT or AT) to 
prevent this. Figure 3 is taken from this article and illustrate the wide range of blood 
lactate values obtained in subjects training at a fixed percentage of their VO2max, 
representing a wide array of metabolic demand.  
 
In 2000, Zacarias and colleagues(81) studied 26 patients with COPD (mean FEV1 49% 
predicted) during incremental exercise on ergocycle, with the goal of evaluating if their 
heart rate at VT (HRVT) expressed as three different methods (%HRpeak, %HR predicted 
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and %HR reserve) fell within the recommended intensity range (+/- 5% of VT). Of note, 
despite using the V-slope method, they could identify VT in 18 patients only. The HRVT 
for the three methods corresponded to a wide range of exercise intensities, and to ensure 
that patients could be trained to +/- 5% of VT, a prescription based on HR alone would 
have had to be 80-85% of HRpeak or 40-45% HRR – which is discordant with current 
guidelines. The authors concluded that exercise prescription based on HR should be 
discouraged in COPD patients, highlighting the need for a different marker to guide 
exercise prescription in these patients. 
 
More recently, Diaz-Buschmann and colleagues(82) studied if using a fixed HR value 
(either with the Karvonen equation or as %HRR) for exercise prescription in 159 patients 
on beta-blocker treatment would result in exercise at too low or too high intensity 
(relative to VT, determined using the VEM). They found that a significant proportion of 
patients would be exercising significantly passed VT, or way below it, depending on the 
HR method used, and that, overall, no fixed HR value resulted in a satisfactory training 
regimen for all patients.  
 
In a study on the use of VT as a guide for exercise prescription in patients with COPD, 
Vallet and colleagues(41) randomized 20 patients with COPD (mean FEV1 about 1.8 l) to 
either an eight week, four times a week active training program at HRVT (using the V-
slope method) or usual care. They noted increases of 25% in symptom-limited VO2 
(VO2SL), 20% in maximal VE, 19% VO2VT and a decrease in VE and respiratory rate 
(RR) for work at 50% and 75% VO2SL. In another study(42), the same investigators 
randomized 24 patients with COPD (mean FEV1 54% and 63% for both arms) to a 4 
week, 5 days a week training program prescribed either using an ‘’individualised’’ 
protocol (HRVT using V-slope) or ‘’standard’’ protocol (using 50% of HRR). The 
individualised protocol (based of HRVT) resulted in significant increase in VO2SL (20%, 
p < 0.05), VO2VT (22%, p < 0.01) and O2 pulse (17%, p < 0.05). The standard protocol 
(based on %HRR) resulted in a significant increase in VO2VT (8%, p < 0.05), but 
significantly less so than the individualized group, and no change in VO2SL or O2 pulse. 
Of note, the actual mean HR during training for both groups was identical – a finding that 
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highlights the importance of trying to identify the personalized HRVT for each patient 
rather than aiming for a generic percentage of HR.  
 
Serres and colleagues(43) studied the adaptation of skeletal muscle to training in 8 COPD 
patients after a short 3-week exercise program, at an intensity corresponding to HRVT, 
and 6 controls. They showed that, along with a significant increase in VO2SL and VO2VT, 
the training group also showed better maximum voluntary contraction (MVC) of the 
quadriceps (+ 8%, p < 0.05), and critical power (+ 39%, p < 0.05). They concluded that 
an individualized training based on HRVT was effective at rapidly increasing peripheral 
muscle performance in COPD patients. 
 
More recently, Gimenez and colleagues(44) randomized 13 COPD patients (mean FEV1 
1.6 l) to either high-intensity training (1 minute at VO2peak alternating with 4 minutes at 
VO2VT) or moderate intensity training (40-50 W), 5 days a week for 6 weeks. The high-
intensity group showed decreased dyspnea at rest (p ≤ 0.01), decreased blood lactate 
levels during exercise (p < 0.001), increased VO2SL, maximal inspiratory and expiratory 
pressures, VE and VO2VT, while decreasing VE/VCO2 (all p ≤ 0.01). The moderate-
intensity group only improved on the 12-minute walk test. These findings support the use 
of the VT as a guide to individualize training regimen in patients with COPD.  
 
It is worth noting that, although the 2013 American Thoracic Society (ATS) guidelines 
on pulmonary rehabilitation recommends using the ACSM framework for exercise 
prescription, they acknowledge that using standard “high-intensity” (high workload) 
training may not be tolerable by COPD patients and that, in this context, a training 
program based on perceived exhaustion (Borg scale rating 4-6) is adequate(34). 
Coincidentally, this level of perceived exhaustion is well known to correspond to the 
VO2VT(70).  
 
Other than exercise prescription, the VT has many other clinical uses. It is known to be 
one of the best predictors of exercise endurance in patients with COPD(84) and an 
important prognostic marker in heart failure(85-88). In patients with primary pulmonary 
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hypertension, VT (measured using V-slope and VEM) stands out as an independent 
marker of disease severity(89), and in patients with idiopathic pulmonary fibrosis (IPF), a 
value of VE/VCO2 ≥ 45 when measured at VT was an independent predictor of the 
presence of systolic pulmonary hypertension and worse survival(90). 
 
Finally, VT is a significant prognostic marker in the peri-operative context. Older and 
colleagues(91) showed that, in 187 elderly patients undergoing major abdominal surgery, 
a pre-operative VO2VT < 11 ml/kg/min was associated with a major increase in per-
operative mortality rate (18% vs 0.8%, p < 0.001). Torchio and colleagues(92) studied the 
outcome of 54 COPD patients after lung-resection surgery and found that a pre-operative 
VT < 14.5 ml/kg/min could predict severe post-operative complications with a sensitivity 
of 91.6% and a specificity of 97.6%. Finally, West and colleagues(93) recently showed 
that, when using multiple physiological parameters to predict complications following 
colonic resection surgery, a multivariable logistic regression model identified only VO2VT 
and sex as reliable predictors of complications (with area under curve 0.71).  
 
4.3 Variance in the measure of VT 
 
4.3.1 Manual measure of VT 
 
As mentioned previously, the identification of VT during exercise relies on a manual 
manipulation by an observer. When using the V-slope method, the observer has to 
manually draw tangent lines on the graph of VCO2 vs VO2 to identify the inflection point 
in their relationship, and when using the VEM, the precise identification of the point 
where VE/VO2 increases without change in VE/VCO2 can be made difficult by the 
inherent irregularities of the graph(63). Alterations in breathing pattern (i.e. 
hyperventilation or irregular breathing) are expected to increase the potential difficulty of 
an observer to identify a precise VT by making the relationships between the different 
variables less clear. In patients with COPD, these alterations could be expected to be 
more prominent, as anomalies in breathing pattern are ubiquitous in this disease, 
especially during exercise(23, 34, 36, 49, 94, 95). Although the V-slope method was 
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initially presented as having the advantage of being independent of VE(57), evidence 
suggests that: 1) both in healthy and COPD patients, the V-slope sometimes fails to 
identify VT(81, 96) and 2) as discussed in section 4.2.2.2, VCO2 measured at the mouth 
is dependent on VE(61, 63), and therefore the V-slope method can be expected to be 
influenced by anomalies in VE. Thus, the inter-observer variance in the measure of VT 
has the potential of being large in the presence of ventilatory anomalies – a concerning 
finding that could pose problem when trying to use the VT for clinical purposes. Despite 
these implications, relatively few studies have evaluated this question. 
 
Yeh and colleagues(51) studied the inter-observer variance of the VEM on 8 healthy 
subjects undergoing incremental exercise testing using measures made by 4 experienced 
physiologists. The mean standard deviation of the VT value for each subject was 8% of 
VO2peak, equivalent to +/- 289 ml. For one subject, the range between the largest and 
smallest determination of VO2VT reached 890 ml/min (24% VO2peak). They concluded 
that their results cast doubt on the ability of the VEM to reliably identify VT.  
 
Gladden and colleagues(60) used nine experienced observers to determine the inter- and 
intra-observer reliability of the VEM on 24 normal exercise tests. They found a median 
inter-observer correlation coefficient of 0.70 and an excellent intra-observer correlation 
(analysis of duplicate tests) of 0.97. Another study from 1987(97) used 6 healthy subjects 
who each performed CPET six times, and evaluated the capacity of VE, VCO2, R and 
VE/VO2 (VEM) to reliably identify VT. The mean observer error in identifying VT from 
the tests was 24% for VE, 19% for VCO2, 29% for R and 15% for the VEM. For the 
VEM, which stood out as the most precise marker among observers, the error rate 
corresponded to a mean difference in VO2VT of 625 ml/min.  
 
Shimizu and colleagues(98) studied the variance between three observers in the measure 
of VT using the V-slope and the VEM in 17 patients with heart disease and six normal 
controls. The maximal inter-observer difference in VO2VT using both methods was 70 
ml/min, and the overall intraclass correlation coefficient for VO2VT among the reviewers 
was 0.60. V-slope was consistently associated with better agreement between observers.  
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More recently, Filho and colleagues(99) evaluated the inter-observer variability of the VT 
during incremental exercise in 14 healthy volunteers. Unusually, they used a single 
composite measure of VT per observer, derived from the mean of their estimation of V-
slope, VEM, VE x time and R x time. Overall, the mean inter-observer difference in the 
composite measure of VO2VT was 140 ml (equivalent to 2 ml/kg/min). Another group 
from the United Kingdom(100) recently evaluated the V-slope method using nine 
different observers, on 21 incremental exercise tests from patients undergoing pre-
operative evaluation. The technical error of measurement across observers (a measure of 
bias + random error) was 8.1% (i.e 0.9 ml/kg/min).  
 
Finally, the only study investigating the inter-observer reliability of the determination of 
VT in COPD patients was presented by Belman and colleagues in 1992(101). They 
investigated the variance in the determination of VT between two observers using V-
slope and VEM on 29 COPD patients (mean FEV1: 40% predicted), on two separate 
exercise tests. The inter-observer Pearson correlation using VEM was 0.79 for the first 
test (although analyses were performed only on 11 subjects because VT could not be 
identified by both observers in 18 cases) and 0.77 for the second (11 patients analysed), 
and 0.97 for the first test using V-slope (on 9 patients) and 0.98 for the second (on 7 
patients). This suggests the V-slope is better than VEM in patients with COPD, although 
the majority of patients had to be excluded from both analyses (VEM and V-slope) 
because their VT could not be defined by both observers.  
 
In summary, the available evidence, although heterogeneous and prone to methodological 
errors, suggests a wide range of inter-observer reliability when evaluating VT. This may 
be due to differences in the population studied, and in the choice of technique used to 
estimate VT. These results are difficult to generalize and command additional research, 
especially in patients with COPD, where the link between inter-observer variance and 
disease severity and other commanding factors remains to be quantified.  
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4.3.2 Computerized measure of VT 
 
To try to eliminate random measurement bias from human observers, a few studies have 
evaluated the value of automatic computerized algorithms for the identification of VT.  
Orr and colleagues(102) were the first to propose a computer algorithm, based on the 
identification of the breaking point in the increase in VE when plotted against VO2. The 
program is instructed to minimize the pooled residual sum of squares when analyzing the 
best-fit regression model of that graph, and VT is reported as the first break in that model. 
They compared the automatic VT determination to the mean of VT (estimated using VE 
as well) by four human observers, on 37 exercise tests, and found a correlation coefficient 
of 0.94 between the two measures (absolute mean difference 50 ml/min). The study by 
Gladden(60) mentioned earlier also included an analysis VT by a computer (with the 
same protocol as Orr and colleagues) and, when compared to the mean of 9 human 
observers (that used a different method: the VEM) showed poor correlation (0.58).  
A study by Solberg and colleagues(103) used 3 computerized algorithm (V-slope, VEM 
and R) on 12 healthy subjects and found that R had the best correlation to serum lactate 
concentration (AT). Finally, a recent study by Ekkekakis and colleagues(104) evaluated 
nine different computer protocols to estimate VT in healthy patients and showed that, 
although mean correlation between methods was relatively good (0.76-0.81), the absolute 
differences in VO2VT derived from the different protocols were often larger than 500 
ml/min.  
 
Overall, although the initial study by Orr was promising, the advent of many different 
algorithms for VT detection seems to have complicated, rather than simplified, the 
question of automatic VT determination. It seems unlikely that an automated analysis of 
variables as volatile and fluctuating as the ventilatory parameters during exercise will 
supplant a human analysis, which, although burdened with its share of bias, always leaves 
place to clinical judgment.  
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The ventilatory threshold is widely accepted as a marker of aerobic fitness. It is 
commonly used for exercise prescription, assessment of response to an intervention and 
as a prognostic marker in many diseases. Its measurement relies on the accurate 
identification of an inflection point in respiratory kinetics during aerobic exercise. 
Patients with COPD greatly benefit from aerobic training. However, these patients suffer 
from chronic airflow limitation that may alter their ventilatory kinetics and impair our 
ability to reliably identify their VT. The exact magnitude of this effect and its relationship 




5.2.1 Primary research objective: 
 
To quantify and compare the inter-observer reliability of human observers in determining 
VT in control subjects and COPD patients, and to compare the performance of the V-
slope and VEM methods. 
 
5.2.2 Secondary research objectives: 
 
1. To compare human versus computerized analyses of VT. 
2. To determine if the inter-observer variation in the identification of the VT 





We expected that COPD would have a negative impact on the reliability of the 
determination of the VT. More specifically, we hypothesized that: 
 
1. The human inter-observer variation in the identification of the VT would be 
greater for patients with COPD than for healthy controls. 
 
2. The inter-observer reliability would be better with the V-slope method than with 
the ventilatory-equivalent method, both for patients with COPD and healthy 
controls. 
 
3. There would be a significant difference in the identification of the VT by 
clinicians compared with computerized analysis, both for the V-slope method and 
the VEM. 
 
4. Markers of airway obstruction and COPD severity (severity of airflow 
obstruction, presence of chronic hypercapnic respiratory failure and presence of 
significant exercise desaturation) would predict a larger inter-observer variation in 
the measure of the VT. 
 
5. The inter-observer variation in the measure of the VT would correspond to a 
clinically significant difference in the measure of HRVT (greater than 5 bpm). 
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7. Article: Reliability of the determination of the ventilatory 
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The purpose of this study was to determine the inter-observer reliability of the assessment 




VT was identified from incremental exercise testing graphs of 115 subjects (23 controls 
and 23 in each COPD GOLD class) by two human observers and a computer analysis, 
using the V-slope method and the ventilatory equivalent method (VEM). Agreement 
between observers in identifying VO2 at VT (VO2VT) and heart rate at VT (HRVT) across 
disease severity groups were evaluated using intra-class correlation (for humans) and 
Passing-Bablok regression analysis (human vs computer).  
 
Results 
For human observers, ICCs (95% confidence interval) in determining VO2VT were higher 
in controls [0.98 (0.97-0.99) both with V-slope and with VEM] than in COPD patients 
[0.72 (0.60-0.81) with V-slope and 0.64 (0.50-0.74) with VEM]. Passing-Bablok analysis 
showed that human and computerized determination of VO2VT were interchangeable in 
controls, but not in COPD patients. FEV1 and peak minute-ventilation during exercise 
were the only variables independently associated with greater inter-observer differences 
in VO2VT. Inter-observer differences in HRVT ranged from 2±1 beats/minute (controls) to 
10±3 beats/minute (GOLD 4).  
 
Conclusions 
In COPD patients, the reliability of human estimation of VO2VT is less in than in controls 
and not interchangeable with a computerized analysis. This should be taken into account 
when using VT for exercise prescription, as a tool to monitor response to an intervention, 




The concept and definitions of anaerobic and ventilatory thresholds have sparked 
considerable literature and debate over the years. One of the reasons for this may reside 
in the lack of a consensual definition of both concepts and the proliferation of terms used 
to describe them (105). The anaerobic threshold can be defined as the oxygen 
consumption above which aerobic metabolism is supplemented by anaerobic 
mechanisms, and after which a progressive increase in blood lactate concentration and 
metabolic acidosis occur (106). The onset of this pivotal event can be estimated using 
non-invasive techniques based on the non-linear evolution of carbon dioxide production 
(VCO2) and minute-ventilation (VE) relative to VO2 during incremental exercise (the so-
called ventilatory threshold – VT). In particular, the breaking point in the VCO2-VO2 
relationship (V-slope method) (57) and the moment at which there is a rise in the 
ventilatory equivalent for O2 (VE/VO2) without a concomitant rise in ventilatory 
equivalent for VCO2 (VE/VCO2) (the ventilatory equivalent method – VEM) (54) have 
been used to identify VT. Exercise above the VT is associated with reduced exercise 
tolerance, metabolic acidosis, a slowing of oxygen consumption (VO2) and CO2 
production (VCO2) kinetics (47), and a sharp rise in dyspnea (70).  
 
In the clinical setting, VT is used as a predictor of overall aerobic fitness and is 
responsive to training, both in healthy subjects and in patients with chronic diseases (42, 
107). It is a prognostic marker in chronic cardio-respiratory diseases (85-87) and in the 
perioperative period (92, 93). Because of its close relationship with overall exercise 
tolerance, the VT is also useful as a tool for exercise prescription. Patients with chronic 
obstructive respiratory disease (COPD) greatly benefit from exercise training, and 
pulmonary rehabilitation has become a standard of care in the management of these 
patients (34). Compared with healthy individuals however, patients with COPD exhibit a 
marked reduction in exercise tolerance caused in part by expiratory flow limitation and 
dynamic hyperinflation, increased work of breathing, abnormal breathing pattern, high 
VD/VT ratio and gas exchange anomalies (36, 108), and as such, may be unable to tolerate 
prolonged high-intensity training. Training programs using the VT as a tool to guide 
exercise intensity have been safely and successfully used in this population (41-44, 109), 
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and additional data suggest that such an ‘’individualised’’ prescription may offer an 
advantage over ‘’interval-based’’ regimen (80-82).   
 
Both the V-slope and the VEM rely on a manual manipulation by an observer or an 
automated computerized analysis, and as such are prone to variation and error. The 
presence of ventilatory and gas exchange anomalies in patients with COPD may further 
impair the reliable identification of VT using these techniques. A large intra- or inter-
observer variation may have consequences when using the VT for exercise prescription, 
when monitoring response to training or when performing prognostic evaluation in 
patients undergoing surgery or with heart failure that have concomitant COPD. In healthy 
subjects, the high intra-observer reliability of the measurement of the VT has already 
been demonstrated (60), but the inter-observer reliability showed more heterogeneous 
results (51, 60, 97, 99). In patients with COPD, one study (101) showed acceptable inter-
observer variability in the identification of the VT, but was limited by its small sample 
size and the lack of details regarding the clinical characteristics of the patients included.  
 
We hypothesized that COPD severity would negatively impact the inter-observer 
reliability of the identification of the VT as determined from the V-slope method and 
VEM. In accordance, the aims of this study were: 1) to quantify the reliability of human 
observers in determining VT in control subjects and COPD patients; 2) to compare 
human versus computerized analyses of VT, and 3) to evaluate if the inter-observer 
difference in VT identification amounts to a clinically significant difference in the 
corresponding heart rate (HRVT). 
 
7.3 Methods 
This study was based on an analysis of incremental exercise test data from individuals 
who completed an exercise test in the respiratory physiology laboratory at l’Hôpital du 
Sacré-Coeur de Montréal. Data from all pulmonary function tests, exercise tests, and 
blood gas analyses performed since March 2010 are stored in a common database located 
on a stand-alone computer in the physiology laboratory. Data for both COPD patients and 
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A convenience sample of individuals with COPD and controls was selected from the 
aforementioned database. For patients with COPD, inclusion criteria were: age ≥ 40 
years, a history of smoking of at least 20 pack-years, an objective diagnosis of COPD (as 
assessed by clinical evaluation and a spirometry result showing a post-bronchodilator 
FEV1/FVC ratio less than 0.70) and an exercise test duration time of at least 6 minutes. 
This last criterion was implemented to maximise the chance of observing a VT.  
With the assumption that patients with GOLD 4 disease would be less represented in the 
database, they were selected first. The database was then screened to identify, for each 
very severe patient, a matching subject amongst all other severity groups and amongst 
controls. Matching was based on age (+/- 4 years), sex, and body mass index (BMI, +/- 4 
kg/m2). Control subjects were defined as individuals with normal resting pulmonary 
function tests, normal VO2peak (i.e. ≥ 85% VO2max predicted) and normal 
cardiorespiratory response to exercise, and were matched to COPD patients for age, sex 
and BMI (see above). Reasons for referral to CPET in control patients were: unexplained 
dyspnea on exertion (16 patients), pre-operative evaluation (5 patients) and lung cancer 
(2 patients). 
Subjects were excluded from the study if their medical file suggested clinical disease 
worsening or a respiratory exacerbation in the four weeks preceding the exercise test, 
evidence of another condition that could limit exercise performance (asthma, unstable 
coronary heart disease, heart failure, cancer, symptomatic peripheral vascular disease or 
significant osteoarthritis), long-term oxygen therapy, or incomplete baseline evaluations.  
Twenty-three patients with GOLD 4 disease meeting inclusion criteria and having a 
suitable match in all other disease severity groups were identified and included in the 
study (total sample 115 patients). Based on the results of the means and standard 
deviations of the first 65 patients studied, a sample size of 22 patients per disease 
subgroup was necessary to identify a difference on 100 ml/min in VO2VT between 
controls and each COPD group with a power on 80% and α-level of 0.05. 
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7.3.2 Baseline measurements 
Demographic and clinical information were collected from medical files. These include 
age, sex, BMI, ethnicity, current medication, and self-reported smoking status. Lung 
function was assessed using spirometry (for expiratory flow rates), body 
plethysmography (for lung volumes) and single breath-hold technique (for lung diffusion 
capacity for carbon monoxide). All tests were performed and interpreted according to 
American Thoracic Society guidelines in a laboratory at sea level.  
 
7.3.3 Exercise testing 
Symptom-limited incremental exercise tests were performed according to published 
guidelines (110). More specifically, tests were realized on an electromagnetically braked 
cycle ergometer (Ergoline 200, Ergoline, Bitz, Germany), with a protocol including two 
minutes of rest and a three-minute period of initial unloaded cycling. Load was increased 
linearly until exhaustion (ramp was individually determined for each patient by the 
attending physician, based on either previous exercise testing result or expected maximal 
work rate as estimated by overall physical fitness and/or FEV1) with the goal of 
maintaining a cycling speed of 60 revolutions per minute. Breath-by-breath analysis of 
expired gases was performed using electronic analysis (Jaeger Oxycon Pro, CareFusion, 
Hoechberg, Germany). VE, VO2, VCO2, VE/VO2 and VE/VCO2 were computed using 
twenty-second averages of breath-by-breath values. Peak VO2 was the highest 20-second 
mean VO2 obtained. Patients using beta-blockers were not required to withhold them 
before performing CPET. Oxygen saturation was monitored using finger or ear pulse 
oximetry. Exercise capacity was defined as the highest work rate achieved for at least 20 
seconds at a rate of at least 50 revolutions per minute. Arterial blood gases were assessed 
at baseline using a standard blood gas analyzer (ABL800 Flex, Radiometer, Copenhagen, 
Denmark). Dyspnea and leg fatigue were evaluated at rest and at maximal exercise 
intensity using the modified 10-point Borg scale (111). Additional information regarding 
internal quality control can be found in the “Methods” section of the supplemental digital 
content file (Appendix A).  
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7.3.4 Ventilatory threshold 
For all patients, two manual methods were used to identify the VT: 1) the V-slope 
method and 2) the VEM. To optimize the validity of the V-slope method, care was taken 
to ensure that the ranges of VO2 and VCO2 in the plots were equal (57), and that the VO2 
scale was adequate to allow a precise identification of VO2VT. In addition, a computer-
generated analysis of VT (LABManager, version 5.3.0.4, CardinalHealth, Hoechberg, 
Germany) was used, again using both the V-slope method and the VEM. Human 
observers took care to exclude the first minute of exercise from analysis in order to avoid 
confounding VT with a “pseudo-threshold” (112) sometimes associated with 
hyperventilation at the onset of exercise. For all subjects, computerized determination of 
VT was allowed between the onset and the termination of incremental exercise; the 
warm-up and recovery periods were excluded from analysis by the software. In the event 
where a VT could not be identified, it was reported as ‘’undetermined’’.  
 
The VT was reported both as the VO2 at which it occurred (in absolute value) and as the 
corresponding heart rate (HRVT). Graphs for VT analysis for both methods were extracted 
from the database by a research assistant unrelated to the study, coded, duplicated, and 
submitted to two observers (B.P.D and M.M.), who blindly recorded the presence or 
absence of a VT, its value in millilitres of VO2, and the corresponding heart rate. The 
graphs used by the human observers were identical to the ones used for computerized 
analysis. Precise and identical instructions on how to identify VT using both the V-slope 
method and the VEM were given to both observers. For the V-slope method, VT was 
defined as “the breaking point in the line of the graphical representation of VCO2 against 
VO2” (57). For the VEM, VT was defined as “the point where VE/VO2 begins to increase 
while VE/VCO2 remains stable, when both are plotted against VO2” (54).  
 
To test for internal validity, a subsample of 50 graphs drawn randomly from COPD and 
controls was blindly resubmitted to the two observers for a second VT determination. 
Both observers were physicians with formal medical training in respiratory medicine, 
specific training in exercise physiology, but less than 5 years of clinical experience. VT 
analyses were performed in an independent and blinded manner. 
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7.3.5 Statistical analyses 
Agreement between the human observers in the determination of VO2VT was assessed 
using intra-class correlations coefficients (ICC 2,1 – two-way random single measure). 
Reliability using ICC was interpreted according to the following scale: virtually none for 
ICC £ 0.10, slight for ICC 0.11 – 0.40, fair for ICC 0.41 – 0.60, moderate for ICC 0.61 – 
0.80 and substantial for ICC ³ 0.81 (113).  
To test whether human and computer analysis of VO2VT are interchangeable, Bland-
Altman graphical analysis and Passing-Bablok regression analysis was performed (114). 
This non-parametric statistical tool allows the estimation of the interchangeability of two 
analytical methods and of the possible bias between them. It provides a numerical 
quantification of agreement levels and does not make any assumption about the 
distributions of the samples of their measurement errors and is non-sensitive to outliers. It 
does however require that data be continuously distributed and linearly related. 
The mean differences between the two human observers’ assessment of VO2VT were 
compared across disease category groups using one-way ANOVA with post-hoc 
Bonferroni correction.  
A stepwise multiple linear regression analysis that included baseline demographic data 
and pulmonary function and exercise test results was performed to identify independent 
predictors of a larger inter-observer difference in VO2VT. 
The mean inter-observer difference in HRVT for each of the five subgroups was compared 
using one way ANOVA with post-hoc Bonferroni correction. An empirical threshold of 
+/- 5 bpm (total range of 10 bpm) was chosen as the cut-off for clinical significance for 
this parameter, as we believe that when exercise training is based on a target heart rate 
value, the training heart rate should stay within this limit of the objective.  
Intra-observer reliability was assessed using intra-class correlation coefficients. All 
analyses were performed using SPSS version 21 (Chicago, IL, USA) and MedCalc 
(MedCalc Software, Ostend, Belgium). In all instances, a p-value of less than 0.05 was 




The clinical characteristics of the 115 subjects are summarized in Table 1. Most were 
males (70%) and sex, age, and BMI were evenly distributed across subgroups, as 
projected by the recruitment design. Exercise performance evolved as expected with 
increasing COPD severity, with ventilatory limitation and gas exchange abnormalities 
becoming prominent in GOLD 3 and 4 patients.  
 













Sex (number of males) 16 16 16 16 16 
Age (y) 55 (7) 56 (7) 56 (7) 56 (5) 57 (6) 
BMI (kg/m2) 27 (4) 26 (5) 26 (5) 26 (5) 25 (6) 
Beta-blocker use, n 1 6 4 7 7 
Pulmonary function tests 
   FEV1/FVC 76 (3) 64 (3) 57 (8) 41 (7) 36 (7) 
   FEV1 (l) 3.49 (0.63) 2.65 (0.55) 2.21 (0.59) 1.23 (0.33) 0.95 (0.33) 
   FEV1 (% pred.) 111 (15) 86 (6) 70 (7) 39 (6) 28 (2) 
   FVC (l) 4.57 (0.83) 4.04 (0.85) 3.95 (1.22) 2.96 (0.54) 2.55 (0.67) 
   FVC (% pred.) 119 (18) 106 (8) 102 (19) 77 (14) 63 (12) 
   FRC (% pred.) 99 (18) 108 (19) 111 (24) 149 (25) 155 (50) 
   TLC (% pred.) 113 (14) 107 (10) 110 (18) 119 (18) 112 (37) 
   RV (% pred.) 93 (16) 104 (22) 115 (29) 179 (38) 188 (69) 
   DLCO (% pred.) 92 (10) 73 (18) 69 (18) 52 (12) 43 (10) 
Resting hypercapnia (n) 0 0 0 4 5 
Incremental exercise test 
   Ramp (W/min) 14 (3) 12 (5) 11 (4) 9 (5) 7 (4) 
   Peak Power (W) 156 (56) 121 (62) 100 (46) 62 (34) 45 (24) 
   Peak Power (% pred.) 108 (28) 82 (24) 70 (16) 44 (14) 33 (12) 
   Peak Heart rate (bpm) 157 (14) 138 (21) 137 (22) 124 (14) 119 (11) 
   Peak Heart rate (% pred.) 92 (8) 82 (12) 81 (14) 74 (8) 71 (6) 
   Peak VO2 (l/min) 2.20 (0.67) 1.74 (0.64) 1.63 (0.61) 1.27 (0.37) 1.07 (0.31) 
   Peak VO2 (% pred.) 110 (23) 86 (18) 81 (16) 63 (13) 50 (10) 
   Peak VE (l/min) 82 (28) 69 (23) 63 (19) 46 (15) 36 (12) 
   Peak VE (% pred.) 63 (13) 74 (20) 80 (16) 104 (26) 111 (22) 
   Exercise desaturation (n) 0 1 1 2 6 
All data presented as mean (standard deviation) unless stated otherwise. BMI = body mass index. FEV1 = Forced expiratory volume in 
1 second. FVC = forced vital capacity. FRC = functional residual capacity. TLC = total lung capacity. RV = residual volume. DLCO = 
Diffusion capacity of the lung for carbon monoxide. PaCO2 = arterial partial pressure of carbon dioxide. VO2 = oxygen uptake. VE = 
minute-ventilation. Resting hypercapnia = resting PaCO2 ≥ 45 mmHg. Exercise desaturation = a decrease in > 4% saturation during 
exercise. 
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7.4.1 Agreement in the determination of VT for human observers 
There were no instances of “undetermined” VT.  
Table 2 shows the agreement in the determination of VO2VT between human observers, 
assessed using ICC. Overall, reliability between human observers was higher in control 
subjects than in patients with COPD: in control subjects, ICC was 0.98 with V-slope and 
0.98 with VEM, whereas in patients with COPD as a whole, ICC was 0.72 with V-slope 
and 0.64 with VEM. The 95% confidence intervals of ICCs of the controls and COPD 
patients were mutually exclusive. There was also a progressive decline in agreement 
between the two observers with increasing disease severity. In patients with GOLD 4 
disease, agreement reached only “slight” levels.  
 
Table 2. Agreement of human observers in the determination of VO2VT. 
 V-slope VEM 
ICC 95% CI p ICC 95% CI p 
Controls 0.98 0.97 – 0.99 < 0.001 0.98 0.97 – 0.99 < 0.001 
All COPD 0.72 0.60 – 0.81 < 0.001 0.64 0.50 – 0.74 < 0.001 
GOLD 1 0.92 0.83 – 0.96 < 0.001 0.94 0.86 – 0.96 < 0.001 
GOLD 2 0.78 0.53 – 0.90 < 0.001 0.70 0.42 – 0.86 < 0.001 
GOLD 3 0.68 0.38 – 0.85 < 0.001 0.42 0.03 – 0.70 0.02 
GOLD 4 0.35 -0.34 – 0.66 0.04 0.15 -0.23 – 0.51 0.23 
p-values refer to individual intra-class correlations. ICC=intraclass correlation coefficient; CI=confidence interval; VEM=ventilatory 
equivalents method; COPD=chronic obstructive pulmonary disease; GOLD=Global initiative for Obstructive Lung Disease. 
 
ANOVA analysis revealed that the mean absolute differences in the measures of VO2VT 
using V-slope and VEM were statistically greater in COPD patients compared with 
controls, and that this difference increased with severity (table 3). 
 
Table 3. Mean (SD) inter-observer difference in VO2VT (ml/min) according 
to disease severity. 
 V-slope p-value VEM p-value 
Controls 42 (26) - 41 (26) - 
All COPD 189 (115) <0.001 204 (117) <0.001 
GOLD 1 111 (33) 0.12 94 (45) 0.29 
GOLD 2 165 (100) <0.001 194 (103) 0.001 
GOLD 3 209 (125) <0.001 222 (86) <0.001 
GOLD 4 270 (120) <0.001 307 (112) <0.001 




Comparison of human and computer observers in the determination of VO2VT 
E-table 1 and e-figure 1 of the supplemental digital content file (Appendix A) describe 
the results of the Passing-Bablok regression analysis comparing each human observer to 
the computerized analysis. In short, for both human observers, the relationship of VO2VT 
with the computerized analysis did not differ from linearity, confirming that the data can 
be used in Passing-Bablok analysis. Using V-slope, VO2VT values from human observer 1 
were interchangeable with computer analysis for controls, but not for patients with 
COPD. Similar results were obtained using the VEM. In an identical manner, observer 2 
was found to be interchangeable with computerized analysis when evaluating controls, 
but not COPD patients. Additional description of the Passing-Bablok regression analyses 
can be found in the supplemental digital content file (Appendix A). 
Bland-Altman plots for both methods are shown in figure 4, and similarly show that, 
although most data points remain inside of the limits of agreement, COPD patients 




Figure 4. Bland-Altman procedures for inter-observer differences in VO2VT, when using 
(A) the V-slope method and (B) the VEM. The horizontal lines represent the average 
inter-observer difference in VO2VT (center) and 95% limits of agreement (top and 






































































7.4.2 Inter-observer differences in HRVT 
Table 4 summarises the inter-observer differences in the evaluation of HRVT expressed 
both as absolute values and as a percentage of the peak heart rate attained during 
incremental exercise testing. Compared with controls using ANOVA, there was a 
statistically significant gradual increase in the inter-observer difference of HRVT with 
disease severity. On average, only patients in the most severe COPD subgroup reached 
the pre-specified threshold of clinical significance (+/- 5 bpm). For each subgroup of 
patients, there were no significant differences in the mean inter-observer difference in 
HRVT between patients with and without beta-blockers (complete data can be found in e-
table 2 of the supplemental digital content file – Appendix A).  
Table 4. Mean (SD) inter-observer difference in the measure of HR VT (absolute value and %peakHR) using 
two methods, by COPD severity. 
 HRVT - beats per minute HRVT - %peakHR V-slope p VEM p V-slope p VEM p 
Controls 2 (1) - 2 (2) - 1.3 (0.7 - 1.4 (1.1) - 
All COPD 6 (4) <0.001 7 (3) <0.001 4.9 (3.1) <0.001 5.6 (2.7) <0.001 
GOLD 1 3 (2) 0.99 4 (1) 0.01 2.1 (1.4) 0.99 3.0 (1.0) 0.01 
GOLD 2 5 (2) 0.02 6 (2) <0.001 3.5 (1.9) 0.002 4.6 (1.8) <0.001 
GOLD 3 7 (3) <0.001 8 (2) < 0.001 5.0 (2.6) <0.001 6.3 (1.8) < 0.001 
GOLD 4 10 (3) <0.001 10 (3) <0.001 8.3 (2.3) <0.001 8.6 (2.3) <0.001 
HRVT=heart rate at the ventilatory threshold; VEM=ventilatory equivalent method; GOLD=Global initiative for chronic 
Obstructive Lung Disease. 
 
7.4.3 Predictors of a larger inter-observer difference in VO2VT 
Table 5 describes the results of the stepwise multiple linear regression analysis. With V-
slope, FEV1, %predicted and peak minute-ventilation were the two sole independent 
predictors of a larger inter-observer difference in VO2VT (R2=0.41), whereas with VEM, 









Table 5. Multiple linear regression models for the prediction of a larger inter-observer difference 
in VO2VT when using V-slope or VEM.  
 V-slope VEM 
β p β p-value 
FEV1 (%pred) -0.431 <0.001 -0.708 <0.001 
PeakVE (%pred) 0.268 0.007 0.015 0.87 
Age -0.039 0.60 0.029 0.66 
Gender 0.097 0.20 -0.024 0.72 
BMI -0.006 0.94 -0.002 0.97 
FEV1/FVC -0.098 0.58 -0.071 0.65 
FVC (%pred) 0.114 0.42 0.012 0.93 
FRC (%pred) -0.003 0.98 0.066 0.43 
TLC (%pred) 0.022 0.76 0.050 0.46 
RV (%pred) 0.029 0.78 0.079 0.39 
DLCO (%pred) -0.014 0.90 0.048 0.64 
Hypercapnia -0.118 0.13 -0.096 0.18 
Peak workrate (W) 0.053 0.62 0.046 0.61 
Peak HR (% pred) -0.090 0.33 0.117 0.16 
Peak VO2 (% pred) 0.060 0.68 -0.052 0.87 
Desaturation -0.110 0.17 0.108 0.46 
VO2VT=Oxygen uptake at ventilatory threshold; VEM=ventilatory equivalents method; FEV1=Forced expiratory volume in 1 second; 
VE=minute-ventilation; BMI=body mass index; FVC=Forced vital capacity; FRC=Functional residual capacity; TLC=Total lung 
capacity; RV=Residual volume; DLCO=Diffusion capacity for carbon monoxide; Hypercapnia=Baseline PaCO2 > 45 mmHg; 
W=Watt; HR=Heart rate; VO2=oxygen uptake; Desaturation=Decrease of > 4% in saturation during exercise; %pred=percent of 
predicted value. 
 
7.4.4 Internal validity 
Intra-observer ICC measured on a subset of 50 patients showed relatively high reliability 
throughout the spectrum of disease severity (complete data shown in e-table 3 of the 
supplemental digital content file – Appendix A). For both observers and for both methods 
of observation, ICCs across disease severity groups were all higher than 0.81. 
 
7.5 Discussion 
To our knowledge, this is the first study to report on a direct evaluation of the reliability 
of human and computerized identification of VO2VT and HRVT across COPD severity 
groups. Our main results indicate that 1) reliability of human observers in the 
determination of VO2VT is lower in patients with COPD than in controls, for both the V-
slope and VEM methods; 2) human and computerized analyses of VO2VT are 
interchangeable in controls, but not in patients with COPD; 3) FEV1 (percent predicted) 
is an independent predictor of a larger inter-observer difference in measurement of VO2VT 
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(with peak minute-ventilation also being significant for V-slope) and 4) compared to 
controls, the increasing inter-observer disparity in VO2VT assessment in COPD patients 
corresponds to a gradually larger difference in the estimation of HRVT. These combined 
findings suggest that the baseline airflow obstruction and subsequent abnormalities in the 
ventilatory response of patients with COPD during exercise may be a causative factor in 
the increasing variance of inter-observer assessment of VO2VT (21, 108). This supports a 
common impression amongst clinicians that, when represented graphically, the 
ventilatory parameters of patients with COPD produce more irregular and noisy patterns. 
Coupled with the fact that these patients show higher-than-predicted ventilation for any 
work rate, these anomalies seem to hinder the precise identification of a breaking point in 
the kinetics of ventilatory variables.  
 
The available literature on this subject is scarce, especially in patients with COPD, and 
has produced inconsistent results. Our results for control subjects are similar to those of 
Gladden et al. (60), who showed that, in healthy volunteers, the intra-observer reliability 
of the VEM was high (ICC=0.97), that the inter-observer reliability (tested on nine 
observers) was lower (ICC=0.70) and that agreement between a human observer and a 
computerized value of VO2VT was only moderate (ICC=0.58). Filho et al. (99) also 
described similar results in a sample of 14 healthy subjects. In contrast, Garrard et al. (97) 
showed a higher intra-observer error when assessing VO2VT in healthy subjects. In this 
study, inter-observer error reached 29 and 24% using plots of the respiratory exchange 
ratio and VE, but the V-slope and VEM performed better (19% and 15% error, 
respectively). Yeh et al. (51) described a mean range of 560 ml/min among four 
observers trying to identify VO2VT using the VEM in healthy subjects. This is much 
larger than the difference found in our study in control subjects (44 ml/min).  
 
Our results seem in line with those of Belman et al. (101) who studied the intra- and 
inter-observer reliability of the determination of VT in patients with COPD using the V-
slope method and the VEM, on two separate exercise tests. They reported excellent intra-
observer reliability for both method (Pearson correlation 0.97 and 0.99 for the two 
observers) and good inter-observer reliability for all methods (Pearson correlations all 
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higher than 0.74). However, their analysis was performed on a small, uncharacterized 
subset (n=14 at the maximum) of their overall cohort, which contained subjects with 
widely variable FEV1 values. In addition, the use of Pearson correlation to assess 
agreement between observers is often inappropriate (115). Our study used a larger, 
matched, well-characterized population and adds the findings of a progressive decline in 
inter-observer reliability with disease progression and the poor relationship between 
human and automated analysis in patients with COPD. 
The clinical importance of the magnitude of inter-observer differences identified can be 
put into perspective by comparing it to reported improvements in VO2VT following an 
exercise-training program. In patients with moderate to severe COPD, prior studies have 
documented improvements in VO2VT ranging from approximately 83 to 350 ml/min 
following training (41-44). In our study, for moderate to very severe COPD patients, 
inter-observer differences in VO2VT ranged from 165 to 270 ml/min using the V-slope 
and from 194 to 307 ml/min using the VEM. It is therefore likely that inter-observer 
differences in VT determination have an impact on the evaluation of changes in VO2VT 
following an exercise-training program. In contrast, agreement for control subjects was 
much better (less than 50 ml/min difference in VO2VT) suggesting that inter-observer 
differences in VT play a lesser role in this population (116). In addition, our findings 
concerning the low inter-observer reliability of the determination of VO2VT should raise 
caution when using VO2VT or VE/VCO2 at VT as a prognostic marker in patients with 
heart failure or undergoing surgery if these subjects also have concomitant COPD.  
 
Data concerning the reliability of computerized measurements of VT is limited. Most 
manufacturers of exercise testing equipment provide a unique software algorithm and 
these different equations have been shown to provide variable estimates of VT, both 
when using V-slope and the VEM (104). Any comparison of results originating from 
different software calculations must therefore be made with caution. Our data show that 
for control subjects, both human observers could be considered interchangeable with 
computer analysis, which is in line with the results of Santos et al (117). In COPD 
patients however, human and automatic analysis were not interchangeable owing to 
significant systematic and proportional differences. This sheds an interesting light on the 
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use of these computerized algorithms in daily practice, and clinicians may want to take it 
into account when assessing VO2VT using only automated reported values. Indeed, we 
believe these findings emphasize the need for clinicians to manually confirm any 
automated measurements of VT. 
Our choice of using ± 5 bpm as a threshold for a significant difference in HRVT was 
mostly empirical. It seems likely, however, that an error in measurement reaching 10 bpm 
would lead to important differences in the corresponding workrate or VO2. This 
estimation is difficult to quantify as the slope of the HR/VO2 relationship during 
incremental exercise varies among individuals depending on baseline fitness level, use of 
negative chronotropic medication or underlying cardiopulmonary disease. A crude 
estimate of the impact of varying HR values on exercise intensity can be estimated using 
our cohort as a whole, where peakHR was linearly related to peak workrate. Using this 
relationship, a difference of 10 bpm in HR corresponded to an approximately 40W 
difference in workrate, a difference that is arguably clinically significant, especially when 
considering patients with severe disease. 
The optimal training intensity and modality for patients with COPD is an active matter of 
debate. Although current guidelines on pulmonary rehabilitation suggest using the 
American College of Sports Medicine framework for exercise prescription, they 
acknowledge that using standard “high-intensity” training may not be tolerable by COPD 
patients (118) and that, in this context, a training program based on perceived exhaustion 
(Borg scale rating 4-6) is adequate (34). Coincidentally, this level of perceived 
exhaustion is known to correspond to VO2VT (70). Moreover, the safety and efficacy of 
using fixed percentages of heart rate or VO2peak as training targets has been challenged by 
recent publications (80, 82). Our data show that the absolute inter-observer difference in 
HRVT in patients with COPD becomes increasingly large as disease worsens when 
compared to controls. In this context, if HRVT was used a marker for exercise intensity 
prescription in patients with very severe COPD, this target could translate into an 
unacceptably large array of actual training intensity, which could respectively result in 
exercise inducing undue fatigue and intolerance (above VT) or of too low intensity to 
provide benefits (below VT). In the other subgroups of patients, the inter-observer 
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difference in HRVT was less important, and therefore less likely to negatively impact a 
training regimen. 
 
This study has several limitations. First, VT measurement was performed on 
retrospectively collected data and as such there is a chance of selection bias. We tried to 
limit this effect by matching subjects on several relevant clinical parameters. Second, the 
external validity of the study is impaired by our choice of including only patients having 
performed at least six minutes on incremental exercise testing, a duration which might 
not be routinely sustained by the most severe patients with COPD. We believe this 
criterion is valid in a proof-of-concept framework, with the goal of maximizing the 
attainment of a true VT, but needs to be taken into account when generalizing these 
results to a wider COPD population. Third, we recognize that the relative lack of 
experience of the observers (< 5 years) may be of concern. Hansen et al. (119) showed 
that when measuring VT in patients with pulmonary hypertension, the agreement 
between two experienced observers was better than the one between inexperienced 
observers. However, the overall difference in agreement was small: while experienced 
observers had a mean difference of 20 ml/min in their measure of VO2VT between them, 
less experienced observers had a mean difference of 60 ml/min. The clinical relevance of 
such a small difference is unclear. The fact that our two observers strongly agreed with 
each other in patients with milder disease, maintained relatively high intra-observer 
reliability is reassuring.  
Fifth, the choice of using the V-slope and the VEM to measure VT was based on the 
abundance of their use in the literature and the available data regarding their reliability in 
healthy subjects. Current guidelines suggest the use of either techniques when measuring 
VT (110). Although other methods to assess VT have been reported, they are often 
lacking a standardized definition, scarcely used or known to relate closely to the V-slope 
or the VEM (i.e. changes in PETO2 and PETCO2 vs time, VE, VO2, VCO2 or RER vs work 
rate, VE vs VCO2, heart rate inflection point) (120). Therefore, we believe that the choice 
of using these two methods is representative of common clinical practice and allows a 
more thorough comparison the available literature. Sixth, our choice of reporting data 
using 20-second averages of breath-by-breath data could be criticized. This parameter 
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was chosen in accordance with current guidelines concerning the reporting of data during 
CPET(110) and as it allows, in our opinion, a balance between “noise” and the clear 
representation of respiratory kinetics. Whether the use of different time-averaging 
intervals could further influence the detection of VT requires further studies. Finally, the 
differences in ramp increment rate between subgroups are an expected finding, and 
whether this may have had an impact on the determination of VO2VT is unclear. However, 
studies have reported the lack of significant differences in the determination of VO2VT 
between ramp increments of 7 to 23 W/min in patients with heart failure (121), and 
between increments of 20 to 50 W/min in young healthy subjects (122). 
 
7.6 Conclusion 
In conclusion, results from the present study show that the agreement between human 
observers in the determination of VT in patients with COPD is lower than in controls, 
that human and computer analyses of VO2VT are not interchangeable in these patients and 
that these findings are directly related to the severity of airflow obstruction. Furthermore, 
the decline in precision in the identification of VO2VT corresponds to an increasing 
variability when evaluating HRVT. Clinicians should be aware of the discrepancy between 
software and human identification of VT when reporting automated values of VO2VT, and 
these findings should be taken into account when using VT for exercise prescription, as a 
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Symptom-limited incremental exercise tests were performed according to published 
guidelines (110). More specifically, tests were realized on an electromagnetically braked 
cycle ergometer (Ergoline 200, Ergoline, Bitz, Germany), with a protocol including two 
minutes of rest and a three-minute period of initial unloaded cycling. Load was increased 
linearly until exhaustion (ramp was individually determined for each patient by the 
attending physician, based on either previous exercise testing result or expected maximal 
work rate as estimated by overall physical fitness and/or FEV1) with the goal of 
maintaining a cycling speed of 60 revolutions per minute. Breath-by-breath analysis of 
expired gases was performed using electronic analysis (Jaeger Oxycon Pro, CareFusion, 
Hoechberg, Germany). VE, VO2, VCO2, VE/VO2 and VE/VCO2 were computed using 
twenty-second averages of breath-by-breath values. Peak VO2 was the highest 20-second 
mean VO2 obtained. Patients using beta-blockers were not required to stop them prior to 
CPET. Oxygen saturation was monitored using finger or ear pulse oximetry. Exercise 
capacity was defined as the highest work rate achieved for at least 20 seconds at a rate of 
at least 50 revolutions per minute. Arterial blood gases were assessed at baseline using a 
standard blood gas analyzer (ABL800 Flex, Radiometer, Copenhagen, Denmark). 
Dyspnea and leg fatigue were evaluated at rest and at maximal exercise intensity using 
the modified 10-point Borg scale (111). The pneumotachograph and plethysmography 
box used for the tests was calibrated twice a day, while the turbine flow sensor of the 
CPET system was calibrated daily. Gas analyzers for DLCO measurements were 
calibrated before each test. Gas analyzers of the CPET system are calibrated daily using a 
high precision gas cylinder containing 16% O2 and 4% CO2. The O2 cell of the CPET 
system is changed every 18 months, or as soon as gas calibration becomes unstable. The 
cycle ergometer is calibrated using a standard procedure once a year. In the period from 
which the study’s tests were performed (2010-2014), a total of seven technicians operated 
the system in rotations. Six of these seven operators were present during the whole 4-year 
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period. Every operator received training by the same head technician of the laboratory, 
ensuring homogeneity. A structured and clear protocol was implemented for the 
realization of incremental exercise testing. This protocol was approved by the physician 
in charge of the pulmonary function test laboratory and is based on the latest ATS/ACCP 
guidelines. Every technician operating the system is familiar with the protocol, which is 
easily and readily available in written form in the exercise-testing laboratory. Every 
morning, the head technician of the laboratory reviewed the resting and exercise tests 
from the day before to ensure internal quality and conformity with the protocols. In the 
event of an error, the technician responsible for the test was informed, ensuring 
continuous training and retroaction. Physicians supervising the test based their evaluation 
of the ramp increment on the following parameters: the predicted maximal workrate was 
divided by 10 with the goal of reaching a test duration of 8-12 minutes. The resulting 
ramp was adjusted based on the physician’s judgment based on either a previous exercise 
test performed in our institution or lung function, as described. Reference values for 
spirometry, lung function, diffusing capacity and exercise testing were taken from 
standard sources (123-126). 
 
Results 
Comparison of human and computer observers in the determination of VO2VT 
E-table 1 and e-figure 1 describe the results of the Passing-Bablok regression analysis 
comparing each human observer to the computerized analysis. This technique generates a 
regression equation in the form “y=a + bx”, where “a” is the regression line’s intercept 
and “b” its slope. Each of these variables is associated to a 95% confidence interval that 
will explain if their value differ from zero for intercept and value one for slope only by 
chance. If the 95% CI for the intercept includes “0”, it can be concluded that there is no 
significant difference between obtained intercept value and value zero and there is no 
constant difference between two methods. In the same manner, if the 95% CI for “slope” 
includes “1”, it can be concluded that there is no significant difference between obtained 
slope value and value one and there is no proportional difference between two methods. 
In such case we can assume both analytical methods of measurement can be used 
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interchangeably. In addition, Passing-Bablok regression requires both variables to be 
linearly related. The test therefore evaluates if a significant deviation from linearity is 
present before beginning analysis (127).  
For both human observers, the relationship of VO2VT with the computerized analysis did 
not differ from linearity, confirming that the data can be used in Passing-Bablok analysis. 
Using V-slope, VO2VT values from human observer 1 were interchangeable with 
computer analysis for controls (the 95% CI for Intercept and Slope include “0” and “1” 
respectively) but not for patients with COPD (95% CI for Intercept and Slope do not 
include “0” and “1”, respectively). Similar results were obtained using the VEM. In an 
identical manner, observer 2 was found to be interchangeable with computerized analysis 
when evaluating controls, but not COPD patients.  
 
Internal validity 
Intra-observer ICC measured on a subset of 50 patients showed relatively high reliability 
throughout the spectrum of disease severity (see e-table 3). For both observers and for 
both methods of observation, ICCs across disease severity groups were all higher than 
0.81. Although ICCs remained high across disease subgroups, there is a small tendency 




e-table 1. Passing-Bablok regression analysis comparing computer analysis to each human observers.  
 
V-slope VEM 




Observer 1 vs 
computer analysis 149 -546 – 675 0.99 0.53 – 1.77 No 0.89 -313 -1744 – 554 1.41 0.57 – 2.73 No 0.42 
Observer 2 vs 
computer analysis 299 -424 – 729 0.89 0.47-1.61 No 0.78 -282 -1652 – 603 1.43 0.56 – 2.52 No 0.42 
COPD 
Observer 1 vs 
computer analysis -391 -678 – -161 1.43 1.14 –1.80 No 0.13 -697 -1153 – -431 1.71 1.36 – 2.16 No 0.08 
Observer 2 vs 




e-table 2. Mean (SD) inter-observer difference in HRVT according to the use of beta-
blockers 
 V-slope VEM 
BB No BB p BB No BB p 
Controls* 2 (-) 2 (1) 0.94 2 (-) 2 (2) 0.96 
All COPD 7 (4) 6 (3) 0.41 7 (4) 7 (3) 0.95 
GOLD 1 3 (1) 3 (2) 0.73 4 (2) 4 (1) 0.74 
GOLD 2 3 (1) 5 (2) 0.06 7 (1) 6 (2) 0.52 
GOLD 3 7 (2) 6 (3) 0.48 7 (3) 8 (2) 0.15 
GOLD 4 11 (3) 9 (2) 0.29 10 (4) 10 (2) 0.64 
Data presented as mean (standard deviation).  
P values refer to comparisons between BB and No BB for each severity subgroup, using independent-
samples t-tests. 
*=only 1 subject with BB in this group. 
HRVT=heart rate at the ventilatory threshold; BB=beta-blockers; VEM=ventilatory equivalent method; COPD=chronic 





e-table 3 Intra-observer reliability in the determination of the VO2VT (ml/min) using two methods, on a subset 
of 50 patients. 
 Intra-class correlation - observer 1 Intra-class correlation - observer 2 
V-slope VEM V-slope VEM 
Controls 0.99 0.99 0.99 0.99 
All COPD 0.92 0.91 0.92 0.89 
GOLD 1 0.95 0.96 0.99 0.94 
GOLD 2 0.89 0.90 0.93 0.84 
GOLD 3 0.91 0.87 0.90 0.86 
GOLD 4 0.86 0.82 0.83 0.81 
GOLD = Global initiative for Obstructive Lung Disease. HRVT = heart rate at the ventilatory threshold. VEM = ventilatory equivalent method. VO2VT = 
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